VJOncology is committed to improving our service to you

ASCO 2020 | IMvigor010: atezolizumab for UC

VJOncology is committed to improving our service to you

Thomas Powles

Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, provides an overview of IMvigor010 (NCT02450331), a Phase III, open-label, randomized, multicenter study is to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with observation in participants with muscle-invasive urethelial carcinoma (UC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter